ESR1 and breast cancer: In our standard-of-care therapy resistant ER+ breast cancer cells, treatment with AZD1775 increased gamma-H2AX as a single agent but this signal was diminished when AZD1775 was combined with E2-deprivation/fulvestrant and ribociclib (Figures 8H, F).